Amgen Inc. (NASDAQ:AMGN) Position Trimmed by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 46.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,763,903 shares of the medical research company's stock after selling 2,379,427 shares during the period. Janus Henderson Group PLC owned approximately 0.51% of Amgen worth $720,393,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Kaizen Financial Strategies lifted its stake in shares of Amgen by 35.9% in the fourth quarter. Kaizen Financial Strategies now owns 1,553 shares of the medical research company's stock valued at $405,000 after purchasing an additional 410 shares during the period. Humankind Investments LLC lifted its stake in shares of Amgen by 20.3% in the fourth quarter. Humankind Investments LLC now owns 5,985 shares of the medical research company's stock valued at $1,560,000 after purchasing an additional 1,009 shares during the period. Guardian Wealth Advisors LLC NC lifted its stake in shares of Amgen by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 1,670 shares of the medical research company's stock valued at $435,000 after purchasing an additional 54 shares during the period. Gen Wealth Partners Inc lifted its stake in shares of Amgen by 19.5% in the fourth quarter. Gen Wealth Partners Inc now owns 6,982 shares of the medical research company's stock valued at $1,820,000 after purchasing an additional 1,137 shares during the period. Finally, Gotham Asset Management LLC lifted its stake in shares of Amgen by 1.6% in the fourth quarter. Gotham Asset Management LLC now owns 21,738 shares of the medical research company's stock valued at $5,666,000 after purchasing an additional 333 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on AMGN. Piper Sandler lifted their target price on shares of Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Cantor Fitzgerald began coverage on shares of Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 target price for the company. Erste Group Bank cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Johnson Rice set a $294.00 target price on shares of Amgen in a research report on Wednesday, March 5th. Finally, Bank of America lifted their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has a consensus rating of "Hold" and a consensus price target of $310.23.

Amgen Stock Down 3.0%

Shares of NASDAQ AMGN traded down $8.17 during trading on Wednesday, reaching $262.28. 3,927,755 shares of the stock were exchanged, compared to its average volume of 2,786,150. The business's 50-day moving average price is $293.04 and its 200 day moving average price is $288.89. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $141.03 billion, a price-to-earnings ratio of 34.74, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm's quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.96 earnings per share. As a group, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.63%. Amgen's dividend payout ratio is presently 86.86%.

Insider Activity at Amgen

In related news, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at $11,240,533.68. This represents a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.76% of the stock is currently owned by corporate insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.